Clinical Trial Update: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Phase 2 study of BI-764198 in people with focal segmental glomerulosclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Focal Segmental Glomerulosclerosis

Drugs mentioned

• BI 764198 (BI-764198)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Kidney Disease, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2026-01-12